Development and Preclinical Evaluation of Six-Transmembrane Epithelial Antigen of Prostate 2 Targeted PET Probes: A Case of Drug Repurposing Based on Molecular Docking.
The study presents the first STEAP2-targeted PET probe developed from triptorelin, showing moderate tumor uptake in preclinical models. Further clinical validation is needed before considering its use in human patients.
Where it sits
this study against the rest of the triptorelin corpusSummary and findings
This study evaluated the development of a STEAP2-targeted PET probe using triptorelin in preclinical models. The probe demonstrated moderate tumor uptake and favorable safety profiles. No therapeutic claims are made regarding the use of triptorelin.
Abstract
Six-transmembrane epithelial antigen of prostate 2 (STEAP2) is overexpressed in prostate cancer, yet no STEAP2-targeted imaging probes exist. Using molecular docking, we screened triptorelin and leuprorelin by radioiodine labeling and identified triptorelin as a high-affinity, selective ligand. To enhance in vivo stability and pharmacokinetics, triptorelin underwent acetylation, PEG extension, and 4-iodophenylbutyric acid conjugation, yielding five DOTA-conjugated analogs radiolabeled with 68Ga. In 22Rv1 xenografts, 68Ga-Trip-5 exhibited moderate but specific tumor uptake (SUVmax 1.8) with favorable tumor-to-background contrast. In vivo stability, biodistribution, pharmacokinetics, and human radiation dosimetry (effective dose 0.00345 mSv/MBq) demonstrated favorable safety. Autoradiography on human prostate cancer specimens showed probe accumulation correlating with endogenous STEAP2 expression. This represents the first STEAP2-targeted PET probe developed via molecular docking-guided drug repurposing. Cellular, biochemical, and imaging data provide supportive evidence of STEAP2-mediated targeting. Preclinical performance supports clinical translation of 68Ga-Trip-5, with definitive target validation.
Background
The study addresses the need for imaging probes targeting six-transmembrane epithelial antigen of prostate 2 (STEAP2), which is overexpressed in prostate cancer. Prior to this research, no STEAP2-targeted imaging probes existed. This work is significant as it explores drug repurposing through molecular docking to develop a novel imaging agent.
Methods
The study utilized molecular docking to screen triptorelin and leuprorelin, leading to the identification of triptorelin as a high-affinity ligand. The probe underwent modifications for stability and pharmacokinetics, resulting in five DOTA-conjugated analogs radiolabeled with 68Ga. The primary outcome measure was tumor uptake in 22Rv1 xenografts.
Results
The primary endpoint showed a maximum standardized uptake value (SUVmax) of 1.8 in 22Rv1 xenografts with 68Ga-Trip-5. The effective dose for human radiation dosimetry was reported as 0.00345 mSv/MBq. Autoradiography indicated probe accumulation correlating with STEAP2 expression.
Interpretation
These findings suggest that 68Ga-Trip-5 could be a promising tool for imaging in prostate cancer, although the effect size in terms of clinical significance is not established. The study's preclinical nature and reliance on xenograft models limit the conclusions that can be drawn for human application. Further validation in clinical settings is necessary to confirm the utility of this imaging probe.
Key findings
- SUVmax 1.8 in 22Rv1 xenografts with 68Ga-Trip-5.
- Effective dose 0.00345 mSv/MBq.
- Moderate but specific tumor uptake with favorable tumor-to-background contrast.
Limitations
- Preclinical study with xenograft models.
- No human clinical data reported.
- Limited sample size for efficacy evaluation.